Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for cold pain tolerance in methadone maintenance patients
IRCT20090801002266N17Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of memantine in opioid use disorder (OUD) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Pain onset threshold and Maximum pain tolerance. Started Nov 2021; status: completed.
02
Drugs
memantine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on IRCT20090801002266N17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090801002266N17.